#BiliaryAtresia is the leading cause of liver transplantation in children. This #LiverAwarenessMonth, we’re highlighting the urgent need for new options for patients and families affected by this rare disease.
Learn more: bit.ly/4ynZ9ME

#BiliaryAtresia is the leading cause of liver transplantation in children. This #LiverAwarenessMonth, we’re highlighting the urgent need for new options for patients and families affected by this rare disease.
Learn more: bit.ly/4ynZ9ME
This #LiverAwarenessMonth, we’re raising awareness of #BiliaryAtresia (BA), a rare liver disease that affects newborns and young children.
For more information about BA, visit our website: bit.ly/3VykIN6
#RareDisease #PediatricLiverDisease #Axiomer #RNAEditing #LiverHealth
On Sept 30 at 11a ET join our virtual Investor and Analyst educational event “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing”.
For additional information about the event and to register, visit: www.proqr.com/events
Axiomer Insights: Our team published findings in Scientific Reports on preclinical liver models for ADAR-mediated RNA editing. Monica from our research team discusses how model selection can inform translatability for our #Axiomer #RNAEditing platform.
Read the paper here: bit.ly/3UWJLZz
ProQR welcomes Chris Hart as Chief Data & AI Officer and Thomas Wolf as Strategic AI Advisor to the Board. Their appointments support our strategy to apply AI across discovery and development. AX-0811, the first AI-discovered ProQR program is now in clinical trials.
Duan et al. propose the comparative RNA editomics analytical framework to prioritize potentially adaptive editing sites using multidimensional evidence, including condition specificity and cross-species evolutionary patterns.
doi.org/10.59717/j.t...
#RNAEditing #adaptation
South Korean RNA-editing firm enters Eli Lilly’s San Diego innovation hub to speed its precision gene-therapy pipeline toward the clinic.
Link as first comment.
💡 Interested in light-controlled RNA engineering?
👉 Hanswillemenke et al. use light-controlled RNA-protein conjugates to regulate RNA base editing in living cells.